Ratings Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
67.08 USD +0.07% Intraday chart for Gilead Sciences, Inc. +0.22% -17.20%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • With a 2024 P/E ratio at 30.11 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • With an enterprise value anticipated at 3.55 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-17.20% 83.58B
B-
+25.61% 672B
C+
+25.87% 570B
B
-5.24% 360B
C+
+16.49% 321B
B-
+8.28% 300B
C+
+7.09% 217B
B+
-9.12% 204B
A+
+5.01% 199B
B-
-8.75% 149B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. Ratings Gilead Sciences, Inc.